RECOVERY Collaborative Group 2023, ' Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. ', Lancet (London, England), vol. 401, no. 10387, pp. 1499-1507 . https://doi.org/10.1016/S0140-6736(23)00510-X
Mumford, A D & Gibbison, B J J 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 Dimitriadis, G K 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet, vol. 400, no. 10349, pp. 359-368 . https://doi.org/10.1016/S0140-6736(22)01109-6 RECOVERY Collaborative Group & Dark, P 2022, ' Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis ', Lancet . https://doi.org/10.1016/S0140-6736(22)01109-6
Lancet (London, England) LANCET RECOVERY Collaborative Group 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) a randomised controlled, open-label, platform trial ', The Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Mumford, A D 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised controlled, open-label, platform trial ', Lancet, vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7 Group, RECOVERY C & Dark, P 2021, ' Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. ', Lancet (London, England), vol. 397, no. 10289, pp. 2049-2059 . https://doi.org/10.1016/S0140-6736(21)00897-7
RECOVERY Collaborative Group & Downey, D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', The Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Mumford, A D 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5 Lancet (London, England) Group, RECOVERY C, Felton, T, Dark, P & Mathioudakis, A 2022, ' Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 399, no. 10325, pp. 665-676 . https://doi.org/10.1016/S0140-6736(22)00163-5
Clarke, H, Harvie, M, Lombardelli, C, Krizak, S, Sellers, K, Harrison, H, Lim, Y Y, Parkin, C, Patel, S, Issa, B, Maxwell, A, Wisley, J, Belcher, J, Clarke, R, Howell, T, Crosbie, E & Howell, S 2022, ' The Prevention of Breast and Endometrial cancer using Total Diet Replacement (PROBE-TDR) Trial; Protocol for a Randomised Controlled Trial ', BMJ Open, vol. 12, no. 7, e057161 . https://doi.org/10.1136/bmjopen-2021-057161
RECOVERY Collaborative Group & Downey, D 2021, ' Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 397, no. 10274, pp. 605-612 . https://doi.org/10.1016/S0140-6736(21)00149-5 LANCET Mumford, A, Ramanan, A V & Gibbison, B J J & Welch, H F 2021, ' Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 397, no. 10274, pp. 605-612 . https://doi.org/10.1016/S0140-6736(21)00149-5, https://doi.org/10.1016/S0140-6736(21)00149-5 The Lancet RECOVERY Collaborative Group, Felton, T, Evans, D G, Murray, C, Buch, M & Dark, P 2021, ' Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', Lancet (London, England), vol. 397, no. 10274, pp. 605-612 . https://doi.org/10.1016/S0140-6736(21)00149-5 2021, ' Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 397, no. 10274, pp. 605-612 . https://doi.org/10.1016/S0140-6736(21)00149-5
Europe PubMed Central Lancet (London, England) RECOVERY Collaborative Group & Downey, D 2022, ' Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial ', The Lancet, vol. 399, no. 10320, pp. 143-151 . https://doi.org/10.1016/S0140-6736(21)01825-0 Group, RECOVERY C & Dark, P 2022, ' Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. ', Lancet (London, England), vol. 399, no. 10320, pp. 143-151 . https://doi.org/10.1016/S0140-6736(21)01825-0 Mumford, A D 2022, ' Aspirin in patients admitted to hospital with COVID-19 (RECOVERY) : a randomised, controlled, open-label, platform trial ', Lancet, vol. 399, no. 10320, pp. 143-151 . https://doi.org/10.1016/S0140-6736(21)01825-0